1
|
Pomerantz T, Rubin NJ, Karnezis AN, Zhao X, Brooks R. Primary clear cell carcinoma of the vulva: A case report. Gynecol Oncol Rep 2023; 50:101283. [PMID: 37860082 PMCID: PMC10582292 DOI: 10.1016/j.gore.2023.101283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 09/24/2023] [Accepted: 09/25/2023] [Indexed: 10/21/2023] Open
Abstract
Clear cell carcinoma (CCC) of the vulva is extremely rare. We report a case of a 54-year-old woman who presented with a 5 cm mass of the mons pubis. She underwent needle biopsy demonstrating CCC. She then underwent radical vulvectomy with bilateral inguinofemoral lymph node dissection. Surgical pathology revealed CCC of the vulva with lymphovascular space invasion (LVSI) and metastatic carcinoma in 1/7 inguinal lymph nodes. The patient has a history of endometriosis, raising suspicion that her CCC could have arisen from endometriosis in the mons. She completed adjuvant treatment with cisplatin and concurrent external beam radiation therapy with radiographic evidence of complete response. However, short-interval imaging demonstrated multi-focal recurrence, which was confirmed with supraclavicular lymph node biopsy. She then completed 8 cycles carboplatin, paclitaxel, and biosimilar bevacizumab-bvzr with favorable response on imaging. She was continued on bevacizumab maintenance. She was later started on pembroluzimab for disease progression based on new mediastinal adenopathy and worsening retroperitoneal lymphadenopathy. She received eight cycles of pembrolizumab with ongoing disease progression before enrolling in hospice and discontinuing cancer-directed treatment. As described in the related literature which we summarize here, the majority of reported cases of vulvar CCC arise from endometriosis implants at the site of prior episiotomy or from the Bartholin's gland. This patient had clinical history of endometriosis; prior tissue sampling was not performed to support the diagnosis. Given the absence of data regarding this rare type of primary vulvar cancer, treatment of this patient's disease was based on existing data specific to squamous cell carcinoma of the vulva and extrapolated from treatment guidelines for CCC of the ovary and endometrium. Continued research is needed on this rare form of vulvar carcinoma to determine the risk factors, prognostic factors, and treatment recommendations specific to this disease.
Collapse
Affiliation(s)
- Tali Pomerantz
- Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University of California Davis Medical Center, Sacramento, CA, United States
| | - Nicole J. Rubin
- Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University of California Davis Medical Center, Sacramento, CA, United States
| | - Anthony N. Karnezis
- Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, United States
| | - Xiao Zhao
- Department of Radiation Oncology, University of California Davis Medical Center, Sacramento, CA, United States
| | - Rebecca Brooks
- Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University of California Davis Medical Center, Sacramento, CA, United States
| |
Collapse
|
2
|
Abstract
Endometriosis-associated ovarian malignancies have been well documented. Although these malignancies also occur as extraovarian lesions, little is known about them. Thus, this literature review aimed to further explore these rarely experienced tumors. A total of 257 published cases between April 1990 and April 2020 were found using PubMed, and 212 cases were included in the analysis considering Sampson’s criteria and the history of endometriosis. We classified these cases as follows: intestine, abdominal scar, vagina and vulva, peritoneum and deep endometriosis, urinary tract, uterine cervix, and others. Age of patients, history of endometriosis, types of past hormonal therapy, symptoms, histological types, and treatment were identified. The most common tumor site was the intestine. Endometrioid carcinoma was the dominant histological type. Contrary to the ovary, clear cell carcinoma was rare in extraovarian sites. On the other hand, clear cell carcinoma represented the largest number of abdominal scars. This difference may help us to understand the development of endometriosis-related malignancies. Hormonal treatment was mentioned in 67 cases and estrogen replacement therapy in 33 cases. Although risks of estrogen therapy are still controversial, the highly differentiated histological types and hormone-dependent characteristics of endometriosis-associated malignancy should be considered. Physicians should be careful about estrogen monotherapy after hysterectomy and long-term hormone replacement therapy in patients with a history of endometriosis.
Collapse
|
3
|
Sachdeva M, Ngoi NYL, Lim D, Poon MLM, Thian YL, Lim YW, Lim SE, Tong P, Lum JHY, Ng J, Ilancheran A, Domingo EJ, Low JJH, Tan DSP. PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report. Onco Targets Ther 2021; 14:3921-3928. [PMID: 34234460 PMCID: PMC8254584 DOI: 10.2147/ott.s309661] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 05/05/2021] [Indexed: 11/23/2022] Open
Abstract
Background The optimal treatment and molecular landscape of recurrent clear cell carcinoma of the vulva (VCCC) are unknown. No reported data exist regarding the efficacy of anti-programmed death 1 (PD-1) immune checkpoint inhibition in VCCC. We report on a patient with chemotherapy-refractory recurrent VCCC, who was found to have high tumor programmed death-ligand 1 (PD-L1) combined positive score (CPS), and subsequently experienced a durable partial response (PR), after treatment with off-label fifth-line pembrolizumab. Case Presentation A forty-year-old Filipino woman presented to our center with recurrent VCCC that had progressed on multiple prior lines of cytotoxic chemotherapy. She had a large 25 cm fungating left groin tumor causing marked lower limb lymphedema, pain and limited mobility. PD-L1 CPS by immunohistochemistry was 45. She was treated with off-label pembrolizumab monotherapy and had a dramatic clinical, biochemical and radiological partial response. The progression-free survival of this patient's VCCC after treatment with pembrolizumab, defined as the time from initiation of pembrolizumab until disease progression (by Response Evaluation Criteria in Solid Tumors (version 1.1)), was 8 months. While receiving pembrolizumab, she was diagnosed with concurrent secondary myelodysplastic syndrome with excess blasts (MDS-EB), thought to be related to her prior exposure to multiple lines of cytotoxic chemotherapy. This eventually progressed to acute myeloid leukemia (AML), leading to her demise. Overall survival from time of initiation of pembrolizumab till death was 16 months. Conclusion Pembrolizumab was active in this patient with chemotherapy-refractory VCCC which harbored high PD-L1 CPS. Further studies to determine the role of immune check-point blockade in the treatment of VCCC are warranted.
Collapse
Affiliation(s)
- Manavi Sachdeva
- Department of Medicine, National University Health System Singapore, Singapore, 119074, Singapore
| | - Natalie Y L Ngoi
- Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119228, Singapore
| | - Diana Lim
- Department of Pathology, National University Health System Singapore, Singapore, 119074, Singapore
| | - Michelle L M Poon
- Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119228, Singapore
| | - Yee Liang Thian
- Department of Diagnostic Imaging, National University Health System Singapore, Singapore, 119074, Singapore
| | - Yi Wan Lim
- Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119228, Singapore
| | - Siew Eng Lim
- Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119228, Singapore
| | - Pearl Tong
- Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, National University Hospital Singapore, Singapore, 119074, Singapore
| | - Jeffrey H Y Lum
- Department of Pathology, National University Health System Singapore, Singapore, 119074, Singapore
| | - Joseph Ng
- Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, National University Hospital Singapore, Singapore, 119074, Singapore
| | - Arunachalam Ilancheran
- Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, National University Hospital Singapore, Singapore, 119074, Singapore
| | - Efren J Domingo
- Department of Obstetrics and Gynecology, University of the Philippines College of Medicine, Philippine General Hospital, Manila, 1000, Metro Manila, Philippines
| | - Jeffrey J H Low
- Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, National University Hospital Singapore, Singapore, 119074, Singapore
| | - David S P Tan
- Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119228, Singapore.,Cancer Science Institute, National University of Singapore, Singapore, 117599, Singapore
| |
Collapse
|
4
|
Maillard C, Cherif Alami Z, Squifflet JL, Luyckx M, Jadoul P, Thomas V, Wyns C. Diagnosis and Treatment of Vulvo-Perineal Endometriosis: A Systematic Review. Front Surg 2021; 8:637180. [PMID: 34046423 PMCID: PMC8148344 DOI: 10.3389/fsurg.2021.637180] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 04/06/2021] [Indexed: 11/15/2022] Open
Abstract
Objective: To describe the available knowledge on vulvo-perineal endometriosis including its diagnosis, clinical management and recurrence rate. Methods: We followed the PRISMA guidelines for Systematic Reviews and our study was prospectively registered with PROSPERO (CRD42020202441). The terms “Endometriosis” and “Perineum” or “Vulva” were used as keywords. Cochrane Library, Medline/Pubmed, Embase and Clinicaltrials.gov were searched. Papers in English, Spanish, Portuguese, French or Italian from inception to July 30, 2020 were considered. Reference lists of included articles and other literature source such as Google Scholar were also manually scrutinized in order to identify other relevant studies. Two independent reviewers screened potentially eligible studies according to inclusion criteria. Results: Out of 539 reports, 90 studies were eligible including a total of 283 patients. Their mean age was 32.7 ± 7.6 years. Two hundred sixty-three (95.3%) presenting with vulvo-perineal endometriosis have undergone either episiotomy, perineal trauma or vaginal injury or surgery. Only 13 patients (4.7%) developed vulvo-vaginal endometriosis spontaneously i.e., without any apparent condition favoring it. The reasons that motivated the patients to take medical advice were vulvo-perineal cyclical pain increasing during menstruations (98.2% of the patients, n = 278). Out of the 281 patients for whom a clinical examination was described, 274 patients (97.5%) showed a vulvo-perineal nodule, mass or swelling while six presented with bluish cutaneous lesions (2.1%) and 1 with bilateral polyps of the labia minora (0.4%). All but one patients underwent surgical excision of their lesions but only 88 patients (28.1%) received additional hormonal therapy. The recurrence rate was 10.2% (29 patients) considering a median follow-up period of 10 months (based on 61 studies). Conclusion: In conclusion, vulvo-perineal endometriosis is a rare entity with approximately 300 cases reported in the literature since 1923. With the available knowledge shown in this systematic review, we encourage all practitioners to think about perineal endometriosis in case of perineal cyclical pain with or without previous perineal damage. Diagnosis should be done with clinical exam, perineal ultrasound and pelvic MRI when available. In case of anal sphincter involvement, perianal ultrasound should be performed. Surgical excision of the lesion should be realized in order to remove the lesion and to confirm the diagnosis histologically. Hormonal treatment could be proposed to attempt to decrease the size of a large lesion before surgery or to avoid recurrence of the lesion. As evidence-based approach to the diagnosis, treatment and recurrence rate of affected patients remains a challenge given its low prevalence, the variations in management found in the articles included and the limited quality of available studies, we suggest that a prospective database on vulvo-perineal endometriosis should be generated to increase knowledge but also awareness among healthcare professionals and optimize patients' care. Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, identifier: CRD42020202441.
Collapse
Affiliation(s)
- Charlotte Maillard
- Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Zineb Cherif Alami
- Department of Obstetrics and Gynecology, Clinique Saint-Jean, Brussels, Belgium
| | - Jean-Luc Squifflet
- Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Mathieu Luyckx
- Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.,Tumor Infiltrating Lymphocytes Group - De Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Pascale Jadoul
- Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Viju Thomas
- Department of Obstetrics and Gynecology, Tygerberg Hospital, University of Stellenbosch, Cape Town, South Africa
| | - Christine Wyns
- Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.,Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|